Finance

Lists
600998:SHA
Jointown Pharmaceutical Group Co Ltd
CNÂ¥5.07
0.00%
(0.00) 1D
Sep 8, 3:00:04 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600998...
Open
CNÂ¥5.07
High
CNÂ¥5.10
Low
CNÂ¥5.00
Mkt. cap
25.57B
Avg. vol.
36.70M
Volume
28.74M
Dividend
3.94%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
Jun 8, 2026
P/E ratio
12.92
52-wk high
CNÂ¥5.84
52-wk low
CNÂ¥4.48
EPS
CNÂ¥0.39
Shares outstanding
1.88B
No. of employees
30K
Open
CNÂ¥5.07
High
CNÂ¥5.10
Low
CNÂ¥5.00
Mkt. cap
25.57B
Avg. vol.
36.70M
Volume
28.74M
Dividend
3.94%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
Jun 8, 2026
P/E ratio
12.92
52-wk high
CNÂ¥5.84
52-wk low
CNÂ¥4.48
EPS
CNÂ¥0.39
Shares outstanding
1.88B
No. of employees
30K
Profile
Jointown Pharmaceutical Group Co., Ltd. is a publicly traded multinational healthcare services company. By revenue, it is the largest medical company in China that is not state-owned. It is also the 4th largest overall. Its global headquarters are in Wuhan, China and its international headquarters are in Los Angeles, California. The company specializes in the distribution of pharmaceuticals and medical products, distributing more than 510,000 products. The company also manufactures products, including gloves, surgical masks, medical equipment and medications. In addition, it operates the largest network of medical warehouses in China. It is one of the largest in the world, at over 44 million square feet. The company has over 400 subsidiaries and provides medical products to all 31 provinces in mainland China. Wikipedia
About Jointown Pharmaceutical Group Co Ltd
CEO-
Employees29.9K
Founded2000
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
38.22B
42.06B
44.78B
42.50B
Cost of goods sold
35.00B
38.94B
41.44B
39.06B
Cost of revenue
35.00B
38.94B
41.44B
39.06B
Research and development expenses
31.00M
31.05M
24.25M
35.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.07B
2.21B
2.07B
2.25B
Operating expense
2.18B
2.54B
2.37B
2.14B
Total operating expenses
37.17B
41.49B
43.81B
41.20B
Operating income
1.05B
577.21M
971.28M
1.30B
Other non operating income
-10.19M
-23.03M
-15.38M
-809.73M
EBT including unusual items
706.81M
590.98M
762.47M
810.81M
EBT excluding unusual items
868.16M
402.66M
702.61M
743.17M
Income tax expense
148.37M
258.61M
167.28M
213.41M
Effective tax rate
20.99%
43.76%
21.94%
26.32%
Other operating expenses
7.64M
209.56M
45.26M
84.62M
Net income
529.89M
279.41M
733.16M
467.41M
Net profit margin
1.39%
0.66%
1.64%
1.10%
Earnings per share
0.10
0.05
0.11
0.08
Interest and investment income
65.37M
122.28M
65.73M
319.03M
Interest expense
-245.91M
-262.58M
-319.03M
-65.73M
Net interest expenses
-180.54M
-140.30M
-253.30M
253.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.22B
728.70M
1.12B
1.51B
Gain or loss from assets sale
-238.51M
244.27M
-
20.61M
AI content may include mistakes. Learn more
Google apps